Research Reference
Cortagen
Cortex tetrapeptide bioregulator — cognitive (no validated dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Cortagen is a synthetic cerebral-cortex tetrapeptide (Ala-Glu-Asp-Pro, or AEDP) from the Khavinson family of peptide bioregulators. It has no validated human dose. Research-chemical vendors and self-reported community sources most commonly describe 10 mg lyophilized vials reconstituted and administered as short subcutaneous or intramuscular courses of roughly 10–20 days.
A critical distinction: most human data cited for "cortex peptides" belongs to Cortexin, the injectable polypeptide extract, not to the synthetic Cortagen research chemical, which is backed only by a small preclinical animal and in-vitro literature from its originating laboratory. Extract and synthetic are different products with different evidence bases.
Side Effects & Safety
- No human safety profile has been established for synthetic Cortagen; it is sold labeled "not for human consumption."
- Injection-site reactions (redness, soreness) are the effects most commonly noted in self-reported community sources
- No controlled adverse-event data exist for the synthetic peptide, so its tolerability and long-term safety are unknown
- The preclinical studies cited did not characterize a human toxicity or side-effect profile
- Sterile technique and reconstitution hygiene are the practical concerns most often raised in community references
Research Basis
There is no clinical dose-finding trial for synthetic Cortagen. The dose amounts and course lengths are inherited from the Russian bioregulator tradition — the short, repeatable "course" convention originally applied to injectable tissue extracts — rather than from a study that titrated the synthetic tetrapeptide in people.
The evidence that does exist for the synthetic molecule is small, old, and largely from a single originating laboratory, reporting sciatic-nerve regeneration in a rat model, effects on cortical neurons in tissue culture, and gene-expression changes in animal tissue (PMID 11713572; 15159690; 11276314; 12134478). Independent Western replication is effectively absent.
The proposed mechanism is Khavinson's gene-expression hypothesis — the idea that very short peptides interact with DNA and modulate transcription — a model demonstrated largely in vitro rather than in human tissue (PMID 22117547; 34834147).